Proteomics International Laboratories Ltd (PIQ.AX) Annual Report to Shareholders

It has been a pivotal year for Proteomics International Laboratories Ltd (ASX:PIQ), with the signing of a landmark deal to bring our PromarkerD test for diabetic kidney disease to patients in the United States.

This significant agreement marks Proteomics International's transition from a research and development company to full commercialisation.

Other key milestones in the rollout of PromarkerD include the granting of a CPT PLA reimbursement code in the United States, publication of a Medtech Innovation Briefing in the United Kingdom, and research further demonstrating the clinical utility of the test.

At the same time, Proteomics International is continuing to harness our PromarkerTM technology to develop new diagnostic tests in areas of unmet medical need.

Particularly exciting is the Company's novel test for endometriosis, which this year was shown to correctly identify up to 90 per cent of patients with moderate or severe endometriosis, compared to symptomatic controls.

The Company's work in oesophageal cancer is also showing great promise, with a prototype diagnostic test for oesophageal adenocarcinoma detecting up to 90 per cent of people with the condition.

*To view the Annual Report, please visit:
https://abnnewswire.net/lnk/0DI2000Z

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel 
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367 
E: dirk@candouradvisory.com.au

Kyle Moss
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400
E: kmoss@eurozhartleys.com

News Provided by ABN Newswire